Trial Type: Pancreas Cancer

A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination with Anti-cancer Agents in Participants with Advanced Solid Tumours Expressing Claudin 18.2

A Phase 1 Open-Label Study of PF-07934040 as a Single-Agent and in Combination With Other Targeted Agents in Participants with Advanced Solid Tumors Harboring Mutations in the KRAS Gene.

LS-P-GO44479: A Phase II, Open-Label, Multicenter, Randomized Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran plus Atezolizumab and mFolfirinox versus mFolfirinox Alone in Patients with Respected Pancreatic Ductal Adenocarcinoma

LS-P-Poppy: First-in-class antibody-drug conjugate (ADC) targeting fibronectin (PYX-201) for solid tumors

Gemcitabine, nab-paclitaxel, cemiplimab and motixafortide for first line treatment of stage 4 pancreatic cancer.

A Randomized Phase II Trial of Nab-paclitaxel + Gemcitabine with or without Botensilimab for Metastatic Pancreatic Cancer Who Have Progressed on FOLFIRINOX